DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The information disclosure statements (IDS) submitted on August 8, 2024, September 26, 2024, November 20, 2024, and November 20, 2025 are acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
Specification
The disclosure is objected to because of the following informalities: in paragraphs 0011, 0049, 0051, 0052 and 0283, “urethan” should read “urethane”. Appropriate correction is required.
Claim Objections
Claim 1 is objected to because of the following informalities: in line 3, “urethan” should read “urethane”. Appropriate correction is required.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-14 are rejected under 35 U.S.C. 103 as being unpatentable over Hatakeyama et al. (US 20220079461 A1) in view of Watanabe et al. (US 20190127578 A1).
Regarding Claim 1, Hatakeyama et al. teaches a bio-electrode composition comprising a salt selected from the group consisting of salts of ammonium, sodium, potassium, and silver formed with sulfonamide (see para. 0041-0042, “The bio-electrode composition preferably further comprises . . . a repeating unit-c having a structure selected from the group consisting of salts of ammonium, sodium, potassium, and silver formed with any of fluorosulfonic acid, fluorosulfonimide, and N-carbonyl-fluorosulfonamide”). However, Hatakeyama et al. does not disclose the polymer compound described above as part of the side chain of a compound that has a urethane bond in its main chain.
Watanabe et al. teaches a similar bio-electrode composition comprising a resin component with urethane bonds in its main chain (see para. 0034). Watanabe does not explicitly teach the component’s side chains being formed with sulfonamide salts, but does disclose similar salts as an electro-conductive material present in the bio-electrode composition (see para. 0024). Watanabe also teaches that polyurethanes with side chains can be formed through a reaction between dihydroxy groups and isocyanates (see para. 0060), which is similar to how the instant application forms the claimed invention (see para. 0054).
Therefore, it would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the sulfonamide salt of Hatakeyama et al. by incorporating the teachings of a polyurethane main chain disclosed in Watanabe et al., resulting in a resin component having a urethane bond in its main chain and a salt of ammonium, sodium, potassium, or silver formed with sulfonamide in its side chain. Doing so would aid in adjusting the desired polymer stretchability and strength, a motivation also cited in both Hatekayama et al. (see e.g. para. 0168) and Watanabe et al. (see e.g. para. 0060).
Regarding Claim 2, Hatakeyama et al. teaches the salt polymer described above can be described by the following formula:
PNG
media_image1.png
83
233
media_image1.png
Greyscale
wherein Rf7 can represent a fluorine atom and M+ represents an ion selected from the group consisting of an ammonium ion, a sodium ion, a potassium ion, and a silver ion (see para. 0043).
Watanabe et al. teaches the resin component has a polyether main chain and two side chains (each with silicon-containing groups) as shown by the following formula (see para. 0032):
PNG
media_image2.png
284
386
media_image2.png
Greyscale
A resin component combining the teachings of Hatakeyama et al. and Watanabe et al. would have the sulfonamide side chain replacing the silicone side chains. A foreseeable product of such a reaction would be a component anticipating the claimed formula:
PNG
media_image3.png
227
336
media_image3.png
Greyscale
wherein, as part of the structure of the main chain, following the general structure of polyether-based polyurethanes observable in the resin of Watanabe et al., it would be obvious for:
R1 and R3 to represent a single bond, or a linear or branched alkylene group having 1 or more carbon atoms
R2 to represent a hydrogen atom, a hydroxy group, or a linear or branched alkyl or alkoxy group having 1 or more carbon atoms
and regarding the side chain, following the disclosed structure of the salt polymer described above:
R4 would represent a single bond or a linear, branched, or cyclic hydrocarbylene group having 1 or more carbon atoms, and optionally having a carbonyl group
R5 would be substituted with a fluorine atom
And M+ would represent an ammonium ion, sodium ion, potassium ion, or silver ion.
Therefore, a person having ordinary skill in the art, in view of Hatakeyama et al. and Watanabe et al., and motivated as per Claim 1 above to modify the sulfonamide salt in the bioelectrode composition of Hatakeyama et al. to incorporate urethane bonds in the main chain, would arrive at the claimed invention.
Regarding Claim 3, Watanabe et al. discloses an ammonium ion represented by the following general formula:
PNG
media_image4.png
119
140
media_image4.png
Greyscale
wherein
R1 to R4 each represent a hydrogen atom, a linear, branched, or cyclic alkyl group having 1 to 15 carbon atoms, an alkenyl group having 2 to 12 carbon atoms, or an alkynyl group having 2 to 5 carbon atoms (see para. 0024); and
each optionally have an ether group, an ester group, a carbonyl group, a sulfonyl group, a cyano group, an amino group, a nitro group, hydroxy group, a sulfur atom, sulfonyl group, or a halogen atom, and are optionally bonded to each other to form a ring (see para. 0024).
Although the specific structure of the ammonium ion is not elaborated on in Hatakeyama et al., the ammonium ion for the sulfonamide salt is disclosed generally (see para. 0043) and it would have been obvious for one of ordinary skill in the art before the effective date of the claimed invention to incorporate the teachings of Watanabe to use the specific structure disclosed in Hatakeyama et al. for the combined resin component discussed in the claims above.
Regarding Claims 4-5, Hatakeyama et al. discloses a bio-electrode composition comprising a separate resin selected from the group consisting of a silicone resin, a (meth)acrylate resin, and a urethane resin (see para. 0034).
Regarding Claim 6, Hatakeyama et al. discloses a bio-electrode composition comprising a carbon material and/or a metal powder (see para. 0046).
Regarding Claim 7, Hatakeyama et al. discloses a bio-electrode composition wherein the carbon material is one or both of carbon black and carbon nanotube (see para. 0047).
Regarding Claims 8-9, Hatakeyama et al. discloses a bio-electrode composition wherein the metal powder is a metal powder selected from the group consisting of gold, silver, platinum, copper, tin, titanium, nickel, aluminum, tungsten, molybdenum, ruthenium, chromium, and indium (see para. 0048).
Regarding Claim 10, Hatakeyama et al. discloses a bio-electrode composition comprising an organic solvent (see para. 0051).
Regarding Claim 11, Hatakeyama et al. discloses a bio-electrode composition comprising an electro-conductive base material and a living body contact layer formed on the electro-conductive base material, wherein the living body contact layer is a cured product of the bio-electrode composition (see para. 0053-0054)
Regarding Claim 13, Hatakeyama et al. discloses a method for manufacturing a bio-electrode having an electro-conductive base material and a living body contact layer formed on the electro-conductive base material, the method comprising: applying the bio-electrode composition onto the electro-conductive base material; and curing the bio-electrode composition to form the living body contact layer (see para. 0058-0060).
Regarding Claims 12 and 14, Hatakeyama et al. discloses an electroconductive base material that comprises one or more selected from the group consisting of gold, silver, silver chloride, platinum, aluminum, magnesium, tin, tungsten, iron, copper, nickel, stainless steel, chromium, titanium, carbon, and electro-conductive polymer (see para. 0056).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTIAN M SARCENO ROBLES whose telephone number is (571)272-8786. The examiner can normally be reached M-F: 8:30AM - 5:00PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Stoklosa can be reached at (571) 272-1213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/C.S./ Examiner, Art Unit 3794
/JOSEPH A STOKLOSA/ Supervisory Patent Examiner, Art Unit 3794
Prosecution Insights